In addition, genes affected in a specific pathway vary from tumour to tumour and only a fraction of tumours gain aberrations in well-established cancer-driving genes (for example, TP53, EGFR or RAS), suggesting that there is no single predominant pattern of lung cancer progression. The gene discussed is EGFR; the disease is lung carcinoma.